Main competitors
1m. Revenue rev. 4m. EPS revision 4m. Revenue rev. 1y. EPS revision 1y. Revenue rev. Visibility (Composite) Nbr of analysts
17
27
23
27
22
20
19
20
24
28
23
26
28
23
21
19
14
- 2
18
Average 21
Weighted average by Cap. 23
Other Pharmaceuticals